Can Human Papillomavirus DNA Testing Substitute for Cytology in the Detection of High-Grade Cervical Lesions?

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 3, 2004, Pages 298-302

  Lee, Kyung Ju ^a   Lee, Jae Kwan ^b   Saw, Ho Suk ^b  

^a CHA University   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; CURETTAGE; DNA DETERMINATION; FEMALE; HUMAN; KOREA; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 1542374041     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Kim SJ, Park CK, Lee HP, Namkoong SE, Kang SB, Saw HS. Multiinstitutional study for the development of cervical cancer screening model with new cervicography, PAP smear and HPV DNA test. Korean J Obstet Gynecol. 2001;44: 911-937.
2. Koss LG. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA. 1989;261:737-743.
3. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272-1278.
4. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smear as a predictor of high grade cervical intraepithelial neoplasia. Br J Cancer. 1994;69:167-171.
5. Gaarenstroom KN, Melkert P, Walboomers JM, et al. Human papillomavirus DNA genotypes: prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 1994;4:73-78.
6. Kjaer SK, van den Brule AJ, Bock JE, et al. Human papillomavirus: the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer. 1996;65:601-606.
7. Lorinicz AT, Reid R, Jenson AB, Greegberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of cervix: relative risk association of 15 common anogenital types. Obstet Gynecol. 1992;79:318-327.
8. Franco EL, Ferenczy A. Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to Papanicolaou smear in the triage of women with cervical cytologic abnormalities. Am J Obstet Gynecol. 1999; 181:382-386.
9. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesion: a study of 7932 women. Br J Cancer. 2001;84:1616-1623.
10. Bishop JW, Hartinger JS, Pawlick GF. Time interval effect on repeat cervical smear results. Acta Cytol. 1997;41:269-276.
11. Ronnett BM, Manos MM, Ransley JE, et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and HPV DNA detection. Hum Pathol. 1999;30:816-825.
12. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-1610.
13. Kadish AS, Timmins P, Wang Y, et al. Regression of intracervical neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev. 2002;11:483-488.
14. Kiviat NB, Koutsky LA. Do our current cervical cancer control strategies still make sense? J Natl Cancer Inst. 1996;88:317-318.
15. Swygart C. Human papillomavirus: disease and laboratory diagnosis. Br J Biomed Sci. 1997;54:299-303.
16. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338:423-428.
17. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from high risk area for cervical cancer. J Infect Dis. 1999;180:1415-1423.
18. Burk RD. Pernicious papillomavirus infection. N Engl J Med. 1999;341: 1687-1688.
19. Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999;341:1633-1638.
20. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995; 187:1365-1371.
21. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995;61:306-311.
22. Johnston C. Quantitative tests for human papillomavirus. Lancet. 2000; 355:2179-2180.
23. Lee KR, Manna EA, St John T. Atypical endocervical glandular cells: accuracy of cytologic diagnosis. Diagn Cytopathol. 1995;13:202-208.
24. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet. 2000;355:2194-2198.
25. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretation: realistic estimates from the ASCUS-LSIL triage study. JAMA. 2001;285:1500-1505.
26. Lee KR, Ashfaq R, Birdsong GG, Corkill ME, McIntosh KM, Inhorn SL. Comparison of conventional Papanicolaou smears and a fluid based, thin layer system for cervical cancer screening. Obstet Gynecol. 1997;90:278-284.
27. Robert LM, Gurley AM, Thurloe JK, Bowditch R, Laverty CRA. Evaluation of the ThinPrep Pap test as an adjunct to the conventional Pap smear. Med J Aust. 1997;167:466-469.
28. Papillo JL, Zarka MA, St John TL. Evaluation of the ThinPrep Pap test in clinical practice: a seven month, 16,314 case experience in northern Vermont. Acta Cytol. 1998;42:203-208.
29. Dupree WB, Suprun HZ, Beckwith DG, Shane JJ, Lucente V. The promise and risk of a new technology: the Lehigh Valley Hospital's experience with liquid-based cervical cytology. Cancer. 1998;84:202-207.
30. Hakama M, Chamberlain J, Day NE, Miller AB, Prorok PC. Evaluation of screening programmes for gynaecological cancer. Br J Cancer. 1985;52:669-573.
31. Morrison EAB, Ho GYF, Vermund SH, et al. Human papillomavirus infection and other risk factors for cervical neoplasia: a case control study. Int J Cancer. 1991;49:6-13.
32. Schiffman MH. Epidemiology of cervical human papillomavirus infections. Curr Top Microbiol Immunol. 1994;186:55-81.
33. Meijer CJLM, van den Brule AJC, Snijders PJF, Helmerhorst T, Kenemans P, Wallbumers JMM. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Monogr Eval Carcinog Risks Hum. 1992;119: 271-281.
34. Melkert PW, Hopman E, van den Brule AJ, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993;53:919-923.
35. Wright TC Jr, Lorincz AT, Ferris DG, et al. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smear. Am J Obstet Gynecol. 1998;178:962-966.
36. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer. 1999;81:554-558.
37. Stoler M. Advances in cervical screening technology. Mod Pathol. 2000; 13:275-284.
38. Cuzick J, Sasieni P, Davies P, et al. A systemic review of the role of human papillomavirus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer. 2000;83:561-565.
39. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
40. American Cancer Society. Cancer facts and figures 2003. Available at: http://www.cancer.org
41. Mandelbaltt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287:2372-2381.
42. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83:439-444.
43. Jeanne SM, William FL, Sharita MW, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287:2372-2381.
44. Cuzick J, Sasieni P. Estimates of the cost impact of introducing human papillomavirus testing into a cervical screening programme. In: Franco E, Monsonego J, eds. New Developments of Cervical Cancer Screening and Prevention. Oxford, United Kingdom: Blackwell Scientific Publications, Ltd; 1997:364-372.